<DOC>
	<DOCNO>NCT00766857</DOCNO>
	<brief_summary>The purpose study determine exenatide improve global cardiac function patient type 2 diabetes mellitus congestive heart failure , favorable effect cardiac metabolism lead improvement cardiac efficiency .</brief_summary>
	<brief_title>Effects Exenatide Type 2 Diabetic Patients With Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Type 2 diabetes mellitus Male postmenopausal female Age 18 year Metformin therapy ( stable , maximum tolerable dose 2 month ) HbA1c 6.510 % Confirmed congestive heart failure ( NHYA functional class IIIV ) Ejection fraction &lt; 50 % Patients receive stable standard therapy cardiac condition 3 month prior enter study Type 1 diabetes mellitus Serious renal liver impairment ( Receiving treatment ) malignant disease Cardiovascular event &lt; 3 month prior inclusion Acute congestive heart failure Any reason able sustain image study Pacemaker/ICD Contraindications use exenatide/ insulin Use insulin , thiazolidinediones , incretinbased therapy within 4 month screen Chronic use glucocorticoid , NSAIDs centrally act drug ( &gt; 2 week ) within 2 week immediately prior screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Exenatide</keyword>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Congestive heart failure</keyword>
	<keyword>Incretin hormone</keyword>
	<keyword>GLP-1 agonist</keyword>
	<keyword>Cardiac metabolism</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Cardiac MRI</keyword>
</DOC>